Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Aims The aim of the present paper was to provide an up‐to‐date view on epidemiology and
risk factors of heart failure (HF) development after myocardial infarction. Methods and results …

It has long been observed that heart failure (HF) is associated with measures of systemic
inflammation. In recent years, there have been significant advancements in our …

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and
prognostic tool for the diagnosis and management of heart failure (HF). More recent …

Galectin-3 (Gal-3) regulates basic cellular functions such as cell–cell and cell–matrix
interactions, growth, proliferation, differentiation, and inflammation. It is not surprising …

Heart failure (HF) is a complex syndrome with an enormous societal burden in terms of cost,
morbidity, and mortality. Natriuretic peptide testing is now widely used to support diagnosis …

Aging is the primary risk factor underlying hypertension and incident cardiovascular disease.
With aging, the vasculature undergoes structural and functional changes characterized by …

Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. The
primary prevention of CVD is dependent upon the ability to identify high-risk individuals long …

Objectives: The aim of this study was to examine the relation of galectin-3 (Gal-3), a marker
of cardiac fibrosis, with incident heart failure (HF) in the community. Background: Gal-3 is an …

Background—Galectin-3 has been implicated in the development of organ fibrosis. It is
unknown whether it is a relevant therapeutic target in cardiac remodeling and heart failure …